Jul 20, 2026 08:51AM

Aug 27, 2025 08:00AM

Jul 22, 2025 08:00AM

Jun 30, 2025 08:30AM

Feb 12, 2025 08:00AM

Feb 5, 2025 09:18AM

Dec 9, 2024 08:00AM Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Aug 26, 2024 08:30AM

Aug 12, 2024 08:30AM

Jun 26, 2024 08:56AM

Apr 22, 2024 08:30AM

Apr 15, 2024 08:30AM

Jan 24, 2024 08:30AM

Nov 28, 2023 09:00AM Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

Oct 13, 2023 08:00AM

Sep 26, 2023 08:51AM

May 31, 2023 08:58AM

Mar 30, 2023 09:00AM

Dec 22, 2022 07:30AM

Dec 14, 2022 08:52AM

Oct 10, 2022 08:00AM Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients

326,111 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All